Half-year report · Q2
6960.TEDINET S100UR0K
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥140.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥14.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥27.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.1bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥11.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥14.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥18.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥9.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥204.8bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥209.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥210.8bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥32.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥40.1bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥172.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥169.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥171.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥64.2bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥60.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥61.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥67.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥17.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥267.34 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥622.44 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥324.32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 84.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥17.8bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥17.8bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥658m |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥64.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥64.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥737m |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥66.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥66.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥14.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 514
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration | 66541000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 13026000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 3755000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 29279000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 20480000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 66541000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 66541000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 2382000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 737000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 6736000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 4095000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 13951000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 13951000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 11888000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 4136000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 30500000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 17789000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 64314000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 64314000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 11888000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 4136000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 30500000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 17789000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 64314000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 64314000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 1761000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 658000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 5612000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 2622000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10654000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 10654000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |